Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Cyteir Therapeutics initiated with an Overweight at JPMorgan » 08:38
07/13/21
07/13
08:38
07/13/21
08:38
CYT

Cyteir Therapeutics

$19.60 /

+0.62 (+3.27%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama initiated coverage of Cyteir Therapeutics with an Overweight rating and $30 price target. The rating is based on the long term potential of the company's lead asset CYT-0851, a first in class RAD51-mediated homologous recombination inhibitor, Rama tells investors in a research note. Data last month showed early signals of activity and a clean safety profile with CYT-0851, which helps validate the program's synthetic lethality / DNA damage response approach, says the analyst.

ShowHide Related Items >><<
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

07/13/21 BofA
BofA starts Cyteir Therapeutics at Buy with $23 price target
07/13/21 Wedbush
Cyteir Therapeutics initiated with an Outperform at Wedbush
07/13/21 Morgan Stanley
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley
07/13/21 BofA
Cyteir Therapeutics initiated with a Buy at BofA
  • 18
    Jun
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

Initiation
BofA starts Cyteir Therapeutics at Buy with $23 price target » 07:45
07/13/21
07/13
07:45
07/13/21
07:45
CYT

Cyteir Therapeutics

$19.60 /

+0.62 (+3.27%)

As previously reported,…

As previously reported, BofA analyst Tazeen Ahmad initiated coverage of Cyteir Therapeutics with a Buy rating and $23 price target. Lead asset CYT0851 can "potentially develop into a pipeline in a product," said Ahmad, noting that it has shown broad activity across various cancer types in preclinical studies. Given development is early, Ahmad is looking toward several data updates on efficacy, safety and duration of effect to better measure 0851's "competitiveness in a diverse landscape of oncology medications," the analyst added.

ShowHide Related Items >><<
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

07/13/21 Wedbush
Cyteir Therapeutics initiated with an Outperform at Wedbush
07/13/21 Morgan Stanley
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley
07/13/21 BofA
Cyteir Therapeutics initiated with a Buy at BofA
  • 18
    Jun
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

Initiation
Cyteir Therapeutics initiated with an Outperform at Wedbush » 07:38
07/13/21
07/13
07:38
07/13/21
07:38
CYT

Cyteir Therapeutics

$19.60 /

+0.62 (+3.27%)

Wedbush analyst Robert…

Wedbush analyst Robert Driscoll initiated coverage of Cyteir Therapeutics with an Outperform rating and $40 price target. The analyst highlights that Cyteir's lead program CYT-0851 inhibits a critical DNA repair pathway, homologous recombination, and is designed to exploit the key dependence of cancer cells on this pathway. Driscoll believes the clinical data generated thus far indicate significant potential for CYT-0851 as monotherapy across a wide variety of tumor types. Moreover, he expects Cyteir to leverage the wide therapeutic index demonstrated to date to broaden clinical development in combination with standard of care chemotherapies and targeted agents such as PARP inhibitors, allowing significant potential upside in earlier settings and additional tumor types.

ShowHide Related Items >><<
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

07/13/21 Morgan Stanley
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley
07/13/21 BofA
Cyteir Therapeutics initiated with a Buy at BofA
  • 18
    Jun
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

Initiation
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley » 06:28
07/13/21
07/13
06:28
07/13/21
06:28
CYT

Cyteir Therapeutics

$19.60 /

+0.62 (+3.27%)

Morgan Stanley analyst…

Morgan Stanley analyst Jeffrey Hung initiated coverage of Cyteir Therapeutics with an Overweight rating and $33 price target. Cyteir is developing inhibitors to target cancers overexpressing DNA damaging genes and its initial human data are "encouraging," Hung tells investors. The company's lead drug candidate, CYT-0851, is expected to begin a Phase 2 monotherapy study and a Phase 1/2 combination study with standard of care therapies later this year, Hung noted.

ShowHide Related Items >><<
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

07/13/21 BofA
Cyteir Therapeutics initiated with a Buy at BofA
  • 18
    Jun
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

Initiation
Cyteir Therapeutics initiated with a Buy at BofA » 06:03
07/13/21
07/13
06:03
07/13/21
06:03
CYT

Cyteir Therapeutics

$19.60 /

+0.62 (+3.27%)

BofA initiated coverage…

BofA initiated coverage of Cyteir Therapeutics with a Buy rating and $23 price target.

ShowHide Related Items >><<
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

  • 18
    Jun
CYT Cyteir Therapeutics
$19.60 /

+0.62 (+3.27%)

On The Fly
Opening Day: Moving iMage moves up on market debut » 08:12
07/10/21
07/10
08:12
07/10/21
08:12
SNTG

Sentage

$34.25 /

-13.75 (-28.65%)

, RNAZ

Transcode Therapeutics

$5.26 /

-0.74 (-12.33%)

, AGRI

AgriFORCE Growing Systems

$5.60 /

+0.82 (+17.15%)

, MITQ

Moving iMage

$16.10 /

-7.28 (-31.14%)

, LDOC

LinkDoc Technology

/

+

, DIDI

DiDi

$12.04 /

+0.815 (+7.26%)

, BABA

Alibaba

$206.00 /

+6.04 (+3.02%)

, CYT

Cyteir Therapeutics

$18.70 /

+0.185 (+1.00%)

, FEMY

Femasys

$7.29 /

+0.02 (+0.28%)

, DNAY

Codex DNA

$17.23 /

-0.06 (-0.35%)

, AMAM

Ambrx Biopharma

$21.67 /

+0.68 (+3.24%)

, TRMR

Tremor International

$20.98 /

+2.06 (+10.89%)

, ATAI

Atai Life Sciences

$18.62 /

-1.06 (-5.39%)

, IPSC

Century Therapeutics

$27.35 /

+0.69 (+2.59%)

, VERV

Verve Therapeutics

$46.11 /

-0.09 (-0.19%)

, LYEL

Lyell Immunopharma

$15.87 /

+0.62 (+4.07%)

, ISPC

iSpecimen

$6.48 /

+0.13 (+2.05%)

, HOOD

Robinhood

/

+

, RGCB

Regencell Bioscience

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, BLND

Blend

/

+

, SCAN

Perspectum Group

/

+

, VTEX

VTEX

/

+

, GAMB

Gambling.com

/

+

, DUOL

Duolingo

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, RXST

RxSIGHT

/

+

Shares of Moving iMage…

ShowHide Related Items >><<
VERV Verve Therapeutics
$46.11 /

-0.09 (-0.19%)

HOOD Robinhood
/

+

DNAY Codex DNA
$17.23 /

-0.06 (-0.35%)

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

CYT Cyteir Therapeutics
$18.70 /

+0.185 (+1.00%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

AMAM Ambrx Biopharma
$21.67 /

+0.68 (+3.24%)

SNTG Sentage
$34.25 /

-13.75 (-28.65%)

RNAZ Transcode Therapeutics
$5.26 /

-0.74 (-12.33%)

AGRI AgriFORCE Growing Systems
$5.60 /

+0.82 (+17.15%)

MITQ Moving iMage
$16.10 /

-7.28 (-31.14%)

LDOC LinkDoc Technology
/

+

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

07/08/21 Mizuho
Alibaba core EBITA estimates look 10% too high, says Mizuho
07/07/21 Needham
Alibaba may see deceleration in retail sales, says Needham
07/07/21 KeyBanc
Alibaba price target lowered to $270 from $275 at KeyBanc
07/06/21 HSBC
Alibaba price target lowered to $270 from $288 at HSBC
CYT Cyteir Therapeutics
$18.70 /

+0.185 (+1.00%)

FEMY Femasys
$7.29 /

+0.02 (+0.28%)

DNAY Codex DNA
$17.23 /

-0.06 (-0.35%)

AMAM Ambrx Biopharma
$21.67 /

+0.68 (+3.24%)

TRMR Tremor International
$20.98 /

+2.06 (+10.89%)

ATAI Atai Life Sciences
$18.62 /

-1.06 (-5.39%)

07/08/21 Aegis
Atai Life Sciences initiated with a Buy at Aegis
IPSC Century Therapeutics
$27.35 /

+0.69 (+2.59%)

VERV Verve Therapeutics
$46.11 /

-0.09 (-0.19%)

LYEL Lyell Immunopharma
$15.87 /

+0.62 (+4.07%)

06/29/21 Chardan
Iovance data show activity but 'not a home run,' says Chardan
ISPC iSpecimen
$6.48 /

+0.13 (+2.05%)

HOOD Robinhood
/

+

RGCB Regencell Bioscience
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

BLND Blend
/

+

SCAN Perspectum Group
/

+

VTEX VTEX
/

+

GAMB Gambling.com
/

+

DUOL Duolingo
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

RXST RxSIGHT
/

+

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

  • 16
    Jul
  • 08
    Jul
  • 09
    Jul
  • 08
    Jul
  • 30
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 17
    Jun
LDOC LinkDoc Technology
/

+

HOOD Robinhood
/

+

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SNTG Sentage
$34.25 /

-13.75 (-28.65%)

RGCB Regencell Bioscience
/

+

LDOC LinkDoc Technology
/

+

HOOD Robinhood
/

+

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

CYT Cyteir Therapeutics
$18.70 /

+0.185 (+1.00%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

ATAI Atai Life Sciences
$18.62 /

-1.06 (-5.39%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 18:25
06/29/21
06/29
18:25
06/29/21
18:25
POWW

AMMO

$8.81 /

+0.285 (+3.35%)

, VOXX

Voxx

$13.65 /

-0.4 (-2.85%)

, CYT

Cyteir Therapeutics

$19.90 /

+0.2 (+1.02%)

, QUMU

Qumu

$3.83 /

+0.13 (+3.51%)

, AVAV

AeroVironment

$110.20 /

-0.58 (-0.52%)

, ALT

Altimmune

$15.90 /

-0.4 (-2.45%)

, ANGN

Angion Biomedica

$14.31 /

+0.02 (+0.14%)

, REPX

Riley Exploration

$37.33 /

+0.51 (+1.39%)

, GDYN

Grid Dynamics

$17.54 /

-0.58 (-3.20%)

, CERE

Cerevel Therapeutics

$29.57 /

+17 (+135.24%)

, MDB

MongoDB

$383.51 /

-5.495 (-1.41%)

Check out this evening's…

ShowHide Related Items >><<
VOXX Voxx
$13.65 /

-0.4 (-2.85%)

REPX Riley Exploration
$37.33 /

+0.51 (+1.39%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ALT Altimmune
$15.90 /

-0.4 (-2.45%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

04/22/21
Fly Intel: Top five analyst initiations
04/22/21 Lake Street
AMMO initiated with a Buy at Lake Street
04/08/21 Roth Capital
AMMO initiated with a Buy at Roth Capital
VOXX Voxx
$13.65 /

-0.4 (-2.85%)

06/29/21 DA Davidson
Voxx initiated with a Buy at DA Davidson
CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Craig-Hallum
Qumu downgraded to Hold from Buy at Craig-Hallum
06/11/21 Craig-Hallum
Qumu downgraded to Hold from Buy at Craig-Hallum
02/12/21 Lake Street
Synacor downgraded to Hold from Buy at Lake Street
AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

06/23/21 Canaccord
AeroVironment investors focus on upcoming results and potential, says Canaccord
01/15/21 Stifel
AeroVironment downgraded to Hold from Buy at Stifel
01/14/21 Alembic Global
AeroVironment upgraded to Overweight from Neutral at Alembic Global
01/14/21 Baird
AeroVironment upgraded to Outperform after Arcturus deal at Baird
ALT Altimmune
$15.90 /

-0.4 (-2.45%)

06/18/21 Piper Sandler
CureVac data 'leaves the spot open' for Arcturus, says Piper Sandler
06/16/21 JMP Securities
Altimmune price target raised to $53 from $45 at JMP Securities
06/16/21 H.C. Wainwright
H.C. Wainwright says Altimmune has 'potential blockbuster indication' in obesity
06/16/21 Piper Sandler
Altimmune weight loss data 'outstanding,' says Piper Sandler
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
REPX Riley Exploration
$37.33 /

+0.51 (+1.39%)

06/01/21 Truist
Riley Exploration initiated with a Buy at Truist
06/01/21 Truist
Riley Exploration initiated with a Buy at Truist
04/08/21
Fly Intel: Top five analyst initiations
04/08/21 Roth Capital
Riley Exploration initiated with a Buy at Roth Capital
GDYN Grid Dynamics
$17.54 /

-0.58 (-3.20%)

05/03/21 Cantor Fitzgerald
Grid Dynamics assumed with an Overweight at Cantor Fitzgerald
03/08/21 Northland
Grid Dynamics price target raised to $17 from $11 at Northland
03/05/21 Cowen
Grid Dynamics price target raised to $17 from $14 at Cowen
12/16/20 Canaccord
Grid Dynamics price target raised to $15 from $11 at Canaccord
CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

06/18/21 Morgan Stanley
Cerevel Therapeutics initiated with an Overweight at Morgan Stanley
12/10/20 Goldman Sachs
Cerevel Therapeutics initiated with a Buy at Goldman Sachs
11/23/20 Jefferies
Cerevel Therapeutics initiated with a Buy at Jefferies
11/09/20
Fly Intel: Top five analyst initiations
MDB MongoDB
$383.51 /

-5.495 (-1.41%)

06/04/21 Canaccord
MongoDB more upside likely on tap, says Canaccord
06/04/21 Needham
MongoDB price target raised to $415 from $409 at Needham
06/04/21 Mizuho
MongoDB price target raised to $300 from $265 at Mizuho
06/04/21 UBS
MongoDB price target lowered to $300 from $325 at UBS
VOXX Voxx
$13.65 /

-0.4 (-2.85%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

GDYN Grid Dynamics
$17.54 /

-0.58 (-3.20%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ALT Altimmune
$15.90 /

-0.4 (-2.45%)

  • 30
    Jun
  • 02
    Jul
  • 01
    Jul
  • 18
    Jun
  • 12
    Mar
  • 05
    Feb
  • 27
    Jan
  • 01
    Dec
  • 14
    Jul
ALT Altimmune
$15.90 /

-0.4 (-2.45%)

VOXX Voxx
$13.65 /

-0.4 (-2.85%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ALT Altimmune
$15.90 /

-0.4 (-2.45%)

VOXX Voxx
$13.65 /

-0.4 (-2.85%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

Hot Stocks
RA Capital reports 9.4% passive stake in Cyteir Therapeutics » 16:35
06/29/21
06/29
16:35
06/29/21
16:35
CYT

Cyteir Therapeutics

$19.90 /

+0.2 (+1.02%)

RA Capital disclosed a…

RA Capital disclosed a 9.4% stake in Cyteir Therapeutics, which represents over 3.24M shares. The filing does not allow for activism.

ShowHide Related Items >><<
CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

  • 18
    Jun
CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

Hot Stocks
Cyteir Therapeutics Inc trading resumes  09:46
06/25/21
06/25
09:46
06/25/21
09:46
CYT

Cyteir Therapeutics

$17.67 /

+0.17 (+0.97%)

 
ShowHide Related Items >><<
CYT Cyteir Therapeutics
$17.67 /

+0.17 (+0.97%)

  • 18
    Jun
CYT Cyteir Therapeutics
$17.67 /

+0.17 (+0.97%)

Hot Stocks
Cyteir Therapeutics Inc trading halted, volatility trading pause  09:36
06/25/21
06/25
09:36
06/25/21
09:36
CYT

Cyteir Therapeutics

$17.67 /

+1.06 (+6.38%)

 
ShowHide Related Items >><<
  • 18
    Jun
CYT Cyteir Therapeutics
$17.67 /

+1.06 (+6.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.